Literature DB >> 15793257

Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs.

Dale S Edgerton1, Doss W Neal, Melanie Scott, Larry Bowen, Warren Wilson, Charles H Hobbs, Chet Leach, Shantha Sivakumaran, Thomas R Strack, Alan D Cherrington.   

Abstract

The results of the present study, using the conscious beagle dog, demonstrate that inhaled insulin (INH; Exubera) provides better glycemic control during an intraportal glucose load than identical insulin levels induced by insulin (Humulin) infusion into the inferior vena cava (IVC). In the INH group (n = 13), portal glucose infusion caused arterial plasma glucose to rise transiently (152 +/- 9 mg/dl), before it returned to baseline (65 min) for the next 2 h. Net hepatic glucose uptake was minimal, whereas nonhepatic uptake rose to 12.5 +/- 0.5 mg x kg(-1) x min(-1) (65 min). In the IVC group (n = 9), arterial glucose rose rapidly (172 +/- 6 mg/dl) and transiently fell to 135 +/- 13 mg/dl (65 min) before returning to 165 +/- 15 mg/dl (125 min). Plasma glucose excursions and hepatic glucose uptake were much greater in the IVC group, whereas nonhepatic uptake was markedly less (8.6 +/- 0.9 mg x kg(-1) x min(-1); 65 min). Insulin kinetics and areas under the curve were identical in both groups. These data suggest that inhalation of Exubera results in a unique action on nonhepatic glucose clearance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793257     DOI: 10.2337/diabetes.54.4.1164

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  5 in total

1.  Mealtime inhaled insulin lowers fasting glucose: a look at possible explanations.

Authors:  J H Devries
Journal:  Diabetologia       Date:  2005-11-05       Impact factor: 10.122

2.  Inhaled insulin.

Authors:  Emma Morton-Eggleston; Eugene J Barrett
Journal:  BMJ       Date:  2006-05-06

3.  Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine.

Authors:  Dale S Edgerton; Alan D Cherrington; Doss W Neal; Melanie Scott; Margaret Lautz; Nancy Brown; Jeff Petro; Charles H Hobbs; Chet Leach; Angelo Del Parigi; Thomas R Strack
Journal:  J Pharmacol Exp Ther       Date:  2008-12-19       Impact factor: 4.030

4.  Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10.

Authors:  Philip J Kuehl; Alan Cherrington; Dan E Dobry; Dale Edgerton; Dwayne T Friesen; Charles Hobbs; Chet L Leach; Brice Murri; Doss Neal; David K Lyon; David T Vodak; Matthew D Reed
Journal:  AAPS PharmSciTech       Date:  2014-08-09       Impact factor: 3.246

5.  Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

Authors:  Dale S Edgerton; Kathryn M S Johnson; Doss W Neal; Melanie Scott; Charles H Hobbs; Xia Zhang; Alokesh Duttaroy; Alan D Cherrington
Journal:  Diabetes       Date:  2008-10-07       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.